Health Care • Biotechnology: Pharmaceutical Preparations
$144.34 ▲ +2.20
(+1.55%)
MKT CAP: $9.34B • VOL: 325.6K
52W L $75 52W H $161
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$121
MEDIAN
$162
MEAN
$165
HIGH
$196
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE PTGX TAPE
PTGX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $174.65 | $165.99 | 2025-02-14 | $131.35 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $181.87 | $170.32 | 2025-02-06 | $135.68 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $164.55 | $158.77 | 2025-01-29 | $138.57 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $147.23 | — | 2025-01-17 | $141.45 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $127.02 | $137.12 | 2025-01-09 | $128.46 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $171.76 | $150.11 | 2024-12-18 | $125.58 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $140.01 | $145.78 | 2024-12-04 | $134.24 | -4.3% | 48% | C |